Document Detail


Impact of tumour necrosis factor inhibitor treatment on radiographic progression in rheumatoid arthritis patients in clinical practice: results from the nationwide Danish DANBIO registry.
MedLine Citation:
PMID:  22532636     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OBJECTIVES: To compare radiographic progression during treatment with disease-modifying antirheumatic drugs (DMARD) and subsequent treatment with tumour necrosis factor α inhibitors (TNF-I) in rheumatoid arthritis (RA) patients in clinical practice.METHODS: Conventional radiographs (x-rays) of hands and wrists were obtained ∼2 years before start (prebaseline), at baseline and ∼2 years after start (follow-up) of TNF-I. Clinical data were obtained from the DANBIO registry and the patient files. x-Rays were scored blinded to chronology according to the Sharp/van der Heijde method. Annual radiographic progression rates during the DMARD (prebaseline to baseline x-ray) and TNF-I (baseline to follow-up x-ray) periods were calculated.RESULTS: 517 RA patients (76% women, 80% IgM rheumatoid factor positive, 65% anticyclic citrullinated peptide positive, 40% current smokers, age 54 years (range 21-86), median disease duration 5 years (range 0-57)) were included. Patients were treated with infliximab (61%), etanercept (15%) or adalimumab (24%). During the DMARD period 85% of patients received methotrexate, 51% sulphasalazine and 78% prednisolone. The median DMARD period was 733 days (IQR 484-1002) and the median TNF-I period was 562 days (IQR 405-766). The median radiographic progression rate decreased from 0.7 (IQR 0-2.9) total Sharp score units/year (dTSS) in the DMARD period to 0 (0-0.9) units/year in the TNF-I period (p<0.0001, Wilcoxon). Corresponding mean dTSS values were 2.1 (SD 3.7) versus 0.7 (SD 2.3) units/year (p<0.0001, paired t test). 305 patients progressed (dTSS >0) in the DMARD period compared with 158 patients in the TNF-I period (p<0.0001, χ(2)).CONCLUSION: This nationwide observational study of RA patients documented significantly reduced radiographic progression during TNF-I treatment compared with the previous period of DMARD treatment.
Authors:
Lykke Midtbøll Ornbjerg; Mikkel Ostergaard; Pernille Bøyesen; Niels Steen Krogh; Anja Thormann; Ulrik Tarp; Uta Engling Poulsen; Jakob Espesen; Vibeke Stevenius Ringsdal; Niels Graudal; Gina Kollerup; Dorte Vendelbo Jensen; Ole Rintek Madsen; Bente Glintborg; Torben Christensen; Hanne Lindegaard; Ditte Dencker; Annette Hansen; Anne Rødgaard Andersen; Merete Lund Hetland
Related Documents :
17510766 - Pain after open preperitoneal repair versus lichtenstein repair: a randomized trial.
8703146 - Laparoscopic stapler appendectomy. a prospective study of 267 consecutive cases.
23749446 - Leaving more than your fingerprint on the intravenous line: a prospective study on prop...
21461626 - Macroscopic anatomic changes of subcutaneous fat tissue in massive-weight-loss patients.
15128726 - Improving appropriateness of antibiotic therapy: randomized trial of an intervention to...
20619756 - Comparing the effectiveness of q-switched ruby laser treatment with that of q-switched ...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-4-24
Journal Detail:
Title:  Annals of the rheumatic diseases     Volume:  -     ISSN:  1468-2060     ISO Abbreviation:  -     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-4-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0372355     Medline TA:  Ann Rheum Dis     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1DANBIO registry and Department of Rheumatology, Copenhagen University Hospital Glostrup, Glostrup, Denmark.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 s...
Next Document:  Serum IL-6 and IL-21 are associated with markers of B cell activation and structural progression in ...